Grand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage ...

Silexion Therapeutics' Latest Data Demonstrates that Subcutaneously Administered SIL204 Reduces Both Primary Tumors and Metastases in Clinically Relevant Orthotopic Models Where Human Pancreatic ...

Grand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA ...

"Our expanded development plan reflects the strength of recent preclinical data and our commitment to addressing the complexities of KRAS-driven cancers,” said Ilan Hadar, Chairman and CEO of Silexion ...

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages ...

Silexion Therapeutics (SLXN) announced an expanded development plan for its next-generation siRNA candidate, SIL204. This strategy integrates systemic administration to target metastatic ...

GRAND CAYMAN - Silexion Therapeutics Corp. (NASDAQ: SLXN), a micro-cap biotechnology firm with a market capitalization of $9.93 million focused on RNA interference (RNAi) therapies, has announced ...

GRAND CAYMAN - Silexion Therapeutics Corp. (NASDAQ: SLXN), a micro-cap biotechnology firm with a market capitalization of $9.93 million focused on RNA interference (RNAi) therapies, has announced an ...

Silexion Therapeutics Corp, a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, announced it has completed an expanded development plan for its ...